Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) EBITDA (2023 - 2025)

Compass Therapeutics' EBITDA history spans 3 years, with the latest figure at -$15.7 million for Q4 2025.

  • For Q4 2025, EBITDA fell 2.62% year-over-year to -$15.7 million; the TTM value through Dec 2025 reached -$66.4 million, down 34.99%, while the annual FY2025 figure was -$66.4 million, 34.99% down from the prior year.
  • EBITDA for Q4 2025 was -$15.7 million at Compass Therapeutics, down from -$14.2 million in the prior quarter.
  • Across five years, EBITDA topped out at -$7.7 million in Q1 2023 and bottomed at -$19.9 million in Q2 2025.
  • The 3-year median for EBITDA is -$13.0 million (2023), against an average of -$13.1 million.
  • The largest annual shift saw EBITDA decreased 0.17% in 2024 before it tumbled 52.58% in 2025.
  • A 3-year view of EBITDA shows it stood at -$12.9 million in 2023, then fell by 18.23% to -$15.3 million in 2024, then decreased by 2.62% to -$15.7 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's EBITDA are -$15.7 million (Q4 2025), -$14.2 million (Q3 2025), and -$19.9 million (Q2 2025).